;PMID: 9010458
;source_file_1225.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..32] = [t:0..32]
;1)sentence:[e:37..155] = [t:37..155]
;2)section:[e:159..263] = [t:159..263]
;3)section:[e:267..386] = [t:267..386]
;4)sentence:[e:390..504] = [t:390..504]
;5)sentence:[e:505..573] = [t:505..573]
;6)sentence:[e:574..698] = [t:574..698]
;7)sentence:[e:700..817] = [t:700..817]
;8)sentence:[e:818..874] = [t:818..874]
;9)sentence:[e:875..987] = [t:875..987]
;10)sentence:[e:988..1322] = [t:988..1322]
;11)sentence:[e:1323..1462] = [t:1323..1462]
;12)sentence:[e:1463..1520] = [t:1463..1520]
;13)sentence:[e:1521..1602] = [t:1521..1602]
;14)sentence:[e:1603..1791] = [t:1603..1791]
;15)sentence:[e:1792..1938] = [t:1792..1938]
;16)sentence:[e:1939..2031] = [t:1939..2031]
;17)sentence:[e:2032..2338] = [t:2032..2338]
;18)sentence:[e:2339..2531] = [t:2339..2531]
;19)sentence:[e:2532..2796] = [t:2532..2796]
;20)section:[e:2800..2844] = [t:2800..2844]

;section 0 Span:0..32
;Lab Invest  1997 Jan;76(1):153-9
(SEC
  (FRAG (RB:[0..3] Lab) (VB:[4..10] Invest) (CD:[12..16] 1997)
        (CC:[17..24] Jan;76-LRB-) (CD:[24..25] 1) (-RRB-:[25..26] -RRB-)
        (CD:[26..30] :153) (::[30..31] -) (CD:[31..32] 9)))

;sentence 1 Span:37..155
;Sporadic and Thorotrast-induced angiosarcomas of the liver manifest frequent
;and  multiple point mutations in K-ras-2.
;[37..45]:malignancy:"Sporadic"
;[50..68]:malignancy:"Thorotrast-induced"
;[69..95]:malignancy:"angiosarcomas of the liver"
;[128..143]:variation-type:"point mutations"
;[147..154]:gene-rna:"K-ras-2"
(SENT
  (S-HLN
    (NP-SBJ
      (NP
        (ADJP
          (ADJP (JJ:[37..45] Sporadic))
          (CC:[46..49] and)
          (ADJP (NN:[50..60] Thorotrast) (HYPH:[60..61] -)
                (VBN:[61..68] induced)))
        (NNS:[69..82] angiosarcomas))
      (PP (IN:[83..85] of)
        (NP (DT:[86..89] the) (NN:[90..95] liver))))
    (VP (VBP:[96..104] manifest)
      (NP
        (ADJP (JJ:[105..113] frequent) (CC:[114..117] and)
              (JJ:[119..127] multiple))
         (NN:[128..133] point) (NNS:[134..143] mutations))
      (PP-LOC (IN:[144..146] in)
        (NP (NN:[147..154] K-ras-2))))
    (.:[154..155] .)))

;section 2 Span:159..263
;Przygodzki RM, Finkelstein SD, Keohavong P, Zhu D, Bakker A, Swalsky PA,
;Soini  Y, Ishak KG, Bennett WP.
(SEC
  (FRAG (NNP:[159..169] Przygodzki) (NNP:[170..172] RM) (,:[172..173] ,)
        (NNP:[174..185] Finkelstein) (NNP:[186..188] SD) (,:[188..189] ,)
        (NNP:[190..199] Keohavong) (NNP:[200..201] P) (,:[201..202] ,)
        (NNP:[203..206] Zhu) (NNP:[207..208] D) (,:[208..209] ,)
        (NNP:[210..216] Bakker) (NNP:[217..218] A) (,:[218..219] ,)
        (NNP:[220..227] Swalsky) (NNP:[228..230] PA) (,:[230..231] ,)
        (NNP:[232..237] Soini) (NNP:[239..240] Y) (,:[240..241] ,)
        (NNP:[242..247] Ishak) (NNP:[248..250] KG) (,:[250..251] ,)
        (NNP:[252..259] Bennett) (NNP:[260..262] WP) (.:[262..263] .)))

;section 3 Span:267..386
;Laboratory of Human Carcinogenesis, National Cancer Institute, National 
;Institutes of Health, Bethesda, Maryland, USA.
(SEC
  (FRAG (NNP:[267..277] Laboratory) (IN:[278..280] of) (NNP:[281..286] Human)
        (NNP:[287..301] Carcinogenesis) (,:[301..302] ,)
        (NNP:[303..311] National) (NNP:[312..318] Cancer)
        (NNP:[319..328] Institute) (,:[328..329] ,) (NNP:[330..338] National)
        (NNPS:[340..350] Institutes) (IN:[351..353] of) (NNP:[354..360] Health)
        (,:[360..361] ,) (NNP:[362..370] Bethesda) (,:[370..371] ,)
        (NNP:[372..380] Maryland) (,:[380..381] ,) (NNP:[382..385] USA)
        (.:[385..386] .)))

;sentence 4 Span:390..504
;Hepatic angiosarcoma (HA) is an uncommon neoplasm associated with known 
;etiologic factors in 25% to 42% of cases.
;[390..410]:malignancy:"Hepatic angiosarcoma"
;[412..414]:malignancy:"HA"
;[431..439]:malignancy:"neoplasm"
(SENT
  (S
    (NP-SBJ
      (NP (JJ:[390..397] Hepatic) (NN:[398..410] angiosarcoma))
      (NP (-LRB-:[411..412] -LRB-) (NN:[412..414] HA) (-RRB-:[414..415] -RRB-)))
    (VP (VBZ:[416..418] is)
      (NP-PRD
        (NP (DT:[419..421] an) (JJ:[422..430] uncommon) (NN:[431..439] neoplasm))
        (VP (VBN:[440..450] associated)
          (NP (-NONE-:[450..450] *))
          (PP-CLR (IN:[451..455] with)
            (NP (VBN:[456..461] known) (JJ:[463..472] etiologic)
                (NNS:[473..480] factors)))
          (PP (IN:[481..483] in)
            (NP
              (NP
                (QP (CD:[484..486] 25) (NN:[486..487] %) (TO:[488..490] to)
                    (CD:[491..493] 42))
                (NN:[493..494] %))
              (PP (IN:[495..497] of)
                (NP (NNS:[498..503] cases))))))))
    (.:[503..504] .)))

;sentence 5 Span:505..573
;It is, however, one of the most common  sarcomas found in the liver.
;[545..553]:malignancy:"sarcomas"
(SENT
  (S
    (NP-SBJ (PRP:[505..507] It))
    (VP (VBZ:[508..510] is) (,:[510..511] ,)
      (ADVP (RB:[512..519] however))
      (,:[519..520] ,)
      (NP-PRD
        (NP (CD:[521..524] one))
        (PP (IN:[525..527] of)
          (NP
            (NP (DT:[528..531] the)
              (ADJP (RBS:[532..536] most) (JJ:[537..543] common))
              (NNS:[545..553] sarcomas))
            (VP (VBN:[554..559] found)
              (NP (-NONE-:[559..559] *))
              (PP-LOC (IN:[560..562] in)
                (NP (DT:[563..566] the) (NN:[567..572] liver))))))))
    (.:[572..573] .)))

;sentence 6 Span:574..698
;The aim of this study was to find was to find  mutations in the K-ras-2
;oncogene in sporadic and Thorotrast (TT)-induced HA.
;[638..645]:gene-rna:"K-ras-2"
;[658..666]:malignancy:"sporadic"
;[671..694]:malignancy:"Thorotrast (TT)-induced"
;[695..697]:malignancy:"HA"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[574..577] The) (NN:[578..581] aim))
      (PP (IN:[582..584] of)
        (NP (DT:[585..589] this) (NN:[590..595] study))))
    (X (VBD:[596..599] was) (TO:[600..602] to) (VB:[603..607] find))
    (VP (VBD:[608..611] was)
      (S-PRD
        (NP-SBJ (-NONE-:[611..611] *))
        (VP (TO:[612..614] to)
          (VP (VB:[615..619] find)
            (NP
              (NP (NNS:[621..630] mutations))
              (PP-LOC (IN:[631..633] in)
                (NP (DT:[634..637] the) (NN:[638..645] K-ras-2)
                    (NN:[646..654] oncogene))))
            (PP (IN:[655..657] in)
              (NP
                (NP (JJ:[658..666] sporadic)
                  (NML-1 (-NONE-:[666..666] *P*)))
                (CC:[667..670] and)
                (NP
                  (ADJP
                    (NML
                      (NML (NN:[671..681] Thorotrast))
                      (NML (-LRB-:[682..683] -LRB-) (NN:[683..685] TT)
                           (-RRB-:[685..686] -RRB-)))
                    (HYPH:[686..687] -) (VBN:[687..694] induced))
                  (NML-1 (NN:[695..697] HA)))))))))
    (.:[697..698] .)))

;sentence 7 Span:700..817
;Point mutations in K-ras-2 were sought in archival, formalin-fixed tissue
;blocks  from 24 patients with angiosarcoma.
;[700..715]:variation-type:"Point mutations"
;[719..726]:gene-rna:"K-ras-2"
;[804..816]:malignancy:"angiosarcoma"
(SENT
  (S
    (NP-SBJ-1
      (NP (NN:[700..705] Point) (NNS:[706..715] mutations))
      (PP-LOC (IN:[716..718] in)
        (NP (NN:[719..726] K-ras-2))))
    (VP (VBD:[727..731] were)
      (VP (VBN:[732..738] sought)
        (NP-1 (-NONE-:[738..738] *))
        (PP-LOC (IN:[739..741] in)
          (NP
            (NP (JJ:[742..750] archival) (,:[750..751] ,)
              (ADJP (NN:[752..760] formalin) (HYPH:[760..761] -)
                    (VBN:[761..766] fixed))
              (NN:[767..773] tissue) (NNS:[774..780] blocks))
            (PP (IN:[782..786] from)
              (NP
                (NP (CD:[787..789] 24) (NNS:[790..798] patients))
                (PP (IN:[799..803] with)
                  (NP (NN:[804..816] angiosarcoma)))))))))
    (.:[816..817] .)))

;sentence 8 Span:818..874
;Of these, 19 cases were sporadic and 5 were  TT-induced.
;[842..850]:malignancy:"sporadic"
;[863..873]:malignancy:"TT-induced"
(SENT
  (S
    (PP-1 (IN:[818..820] Of)
      (NP (DT:[821..826] these)))
    (,:[826..827] ,)
    (S
      (NP-SBJ
        (NP (CD:[828..830] 19) (NNS:[831..836] cases))
        (PP-1 (-NONE-:[836..836] *T*)))
      (VP (VBD:[837..841] were)
        (ADJP-PRD (JJ:[842..850] sporadic))))
    (CC:[851..854] and)
    (S
      (NP-SBJ
        (NP (CD:[855..856] 5))
        (PP-1 (-NONE-:[856..856] *T*)))
      (VP (VBD:[857..861] were)
        (ADJP-PRD (NN:[863..865] TT) (HYPH:[865..866] -)
                  (VBN:[866..873] induced))))
    (.:[873..874] .)))

;sentence 9 Span:875..987
;Mutational analysis was performed by topographic microdissection  with PCR
;amplification followed by genotyping.
(SENT
  (S
    (NP-SBJ-1 (JJ:[875..885] Mutational) (NN:[886..894] analysis))
    (VP (VBD:[895..898] was)
      (VP (VBN:[899..908] performed)
        (NP-1 (-NONE-:[908..908] *))
        (PP-MNR (IN:[909..911] by)
          (NP
            (NP (JJ:[912..923] topographic) (NN:[924..939] microdissection))
            (PP (IN:[941..945] with)
              (NP
                (NP (NN:[946..949] PCR) (NN:[950..963] amplification))
                (VP (VBN:[964..972] followed)
                  (NP (-NONE-:[972..972] *))
                  (PP (IN:[973..975] by)
                    (NP-LGS (NN:[976..986] genotyping))))))))))
    (.:[986..987] .)))

;sentence 10 Span:988..1322
;Specific mutations were  determined by two independent methods: (a) direct
;sequencing of the PCR product  confirmed by rePCR and by using a different
;sequencing primer, and (b) PCR-based  selective enrichment of mutant DNA by
;endonuclease digestion followed by  heteroduplex DNA analysis using
;denaturing gradient gel electrophoresis.
;[1214..1226]:gene-protein:"endonuclease"
(SENT
  (S
    (NP-SBJ-1 (JJ:[988..996] Specific) (NNS:[997..1006] mutations))
    (VP (VBD:[1007..1011] were)
      (VP (VBN:[1013..1023] determined)
        (NP-1 (-NONE-:[1023..1023] *))
        (PP (IN:[1024..1026] by)
          (NP
            (NP (CD:[1027..1030] two) (JJ:[1031..1042] independent)
                (NNS:[1043..1050] methods))
            (::[1050..1051] :)
            (NP
              (LST (LS:[1052..1055] -LRB-a-RRB-))
              (NP
                (NP
                  (NP (JJ:[1056..1062] direct) (NN:[1063..1073] sequencing))
                  (PP (IN:[1074..1076] of)
                    (NP (DT:[1077..1080] the) (NN:[1081..1084] PCR)
                        (NN:[1085..1092] product))))
                (VP (VBN:[1094..1103] confirmed)
                  (NP (-NONE-:[1103..1103] *))
                  (PP-MNR
                    (PP (IN:[1104..1106] by)
                      (NP (NN:[1107..1112] rePCR)))
                    (CC:[1113..1116] and)
                    (PP (IN:[1117..1119] by)
                      (S
                        (NP-SBJ (-NONE-:[1119..1119] *))
                        (VP (VBG:[1120..1125] using)
                          (NP (DT:[1126..1127] a) (JJ:[1128..1137] different)
                              (NN:[1138..1148] sequencing)
                              (NN:[1149..1155] primer))))))))
              (,:[1155..1156] ,) (CC:[1157..1160] and)
              (LST (LS:[1161..1164] -LRB-b-RRB-))
              (NP
                (NP
                  (NP
                    (NP
                      (ADJP (NN:[1165..1168] PCR) (HYPH:[1168..1169] -)
                            (VBN:[1169..1174] based))
                      (JJ:[1176..1185] selective) (NN:[1186..1196] enrichment))
                    (PP (IN:[1197..1199] of)
                      (NP (JJ:[1200..1206] mutant) (NN:[1207..1210] DNA)))
                    (PP (IN:[1211..1213] by)
                      (NP (NN:[1214..1226] endonuclease)
                          (NN:[1227..1236] digestion))))
                  (VP (VBN:[1237..1245] followed)
                    (NP (-NONE-:[1245..1245] *))
                    (PP (IN:[1246..1248] by)
                      (NP-LGS (NN:[1250..1262] heteroduplex)
                              (NN:[1263..1266] DNA) (NN:[1267..1275] analysis)))))
                (VP (VBG:[1276..1281] using)
                  (NP (VBG:[1282..1292] denaturing) (NN:[1293..1301] gradient)
                      (NN:[1302..1305] gel) (NN:[1306..1321] electrophoresis)))))))))
    (.:[1321..1322] .)))

;sentence 11 Span:1323..1462
;Eleven  K-ras-2 point mutations were detected in 7 of 24 (29%) tumors,
;including 5 of 19  (26%) sporadic HA and 2 of 5 (40%) TT-induced HA.
;[1331..1338]:gene-rna:"K-ras-2"
;[1339..1354]:variation-type:"point mutations"
;[1386..1392]:malignancy:"tumors"
;[1419..1430]:malignancy:"sporadic HA"
;[1448..1461]:malignancy:"TT-induced HA"
(SENT
  (S
    (NP-SBJ-1 (CD:[1323..1329] Eleven) (NN:[1331..1338] K-ras-2)
       (NN:[1339..1344] point) (NNS:[1345..1354] mutations))
    (VP (VBD:[1355..1359] were)
      (VP (VBN:[1360..1368] detected)
        (NP-1 (-NONE-:[1368..1368] *))
        (PP (IN:[1369..1371] in)
          (NP
            (NP (CD:[1372..1373] 7))
            (PP (IN:[1374..1376] of)
              (NP
                (NP (CD:[1377..1379] 24)
                  (PRN (-LRB-:[1380..1381] -LRB-)
                    (NP (CD:[1381..1383] 29) (NN:[1383..1384] %))
                    (-RRB-:[1384..1385] -RRB-))
                  (NNS:[1386..1392] tumors))
                (,:[1392..1393] ,)
                (PP (VBG:[1394..1403] including)
                  (NP
                    (NP
                      (NP (CD:[1404..1405] 5))
                      (PP (IN:[1406..1408] of)
                        (NP (CD:[1409..1411] 19)
                          (PRN (-LRB-:[1413..1414] -LRB-)
                            (NP (CD:[1414..1416] 26) (NN:[1416..1417] %))
                            (-RRB-:[1417..1418] -RRB-))
                           (JJ:[1419..1427] sporadic) (NN:[1428..1430] HA))))
                    (CC:[1431..1434] and)
                    (NP
                      (NP (CD:[1435..1436] 2))
                      (PP (IN:[1437..1439] of)
                        (NP (CD:[1440..1441] 5)
                          (PRN (-LRB-:[1442..1443] -LRB-)
                            (NP (CD:[1443..1445] 40) (NN:[1445..1446] %))
                            (-RRB-:[1446..1447] -RRB-))
                          
                          (ADJP (NN:[1448..1450] TT) (HYPH:[1450..1451] -)
                                (VBN:[1451..1458] induced))
                          (NN:[1459..1461] HA))))))))))))
    (.:[1461..1462] .)))

;sentence 12 Span:1463..1520
;There were seven G:C > A:T and  four G:C > T:A mutations.
;[1480..1483]:variation-state-original:"G:C"
;[1486..1489]:variation-state-altered:"A:T"
;[1500..1503]:variation-state-original:"G:C"
;[1506..1509]:variation-state-altered:"T:A"
;[1510..1519]:variation-event:"mutations"
(SENT
  (S
    (NP-SBJ (EX:[1463..1468] There))
    (VP (VBD:[1469..1473] were)
      (NP-PRD
        (NP (CD:[1474..1479] seven)
          (NML (NN:[1480..1483] G:C)
            (PP (SYM:[1484..1485] >)
              (NP (NN:[1486..1489] A:T))))
          (NML-1 (-NONE-:[1489..1489] *P*)))
        (CC:[1490..1493] and)
        (NP (CD:[1495..1499] four)
          (NML
            (NML (NN:[1500..1503] G:C))
            (PP (SYM:[1504..1505] >)
              (NP (NN:[1506..1509] T:A))))
          (NML-1 (NNS:[1510..1519] mutations)))))
    (.:[1519..1520] .)))

;sentence 13 Span:1521..1602
;All seven mutated tumors contained a codon  12-aspartate amino acid
;substitution.
;[1539..1545]:malignancy:"tumors"
;[1558..1567]:variation-location:"codon  12"
;[1568..1577]:variation-state-altered:"aspartate"
;[1578..1601]:variation-type:"amino acid substitution"
(SENT
  (S
    (NP-SBJ (DT:[1521..1524] All) (CD:[1525..1530] seven)
            (VBN:[1531..1538] mutated) (NNS:[1539..1545] tumors))
    (VP (VBD:[1546..1555] contained)
      (NP (DT:[1556..1557] a)
        (NML
          (NML (NN:[1558..1563] codon) (CD:[1565..1567] 12))
          (HYPH:[1567..1568] -)
          (NML (NN:[1568..1577] aspartate)))
        
        (NML (JJ:[1578..1583] amino) (NN:[1584..1588] acid))
        (NN:[1589..1601] substitution)))
    (.:[1601..1602] .)))

;sentence 14 Span:1603..1791
;In addition, a second codon 12-cysteine  mutant cell population was present
;in one of two codon 12-aspartate mutated  TT-induced HA and in three of five
;codon 12-aspartate sporadic tumors.
;[1625..1633]:variation-location:"codon 12"
;[1634..1642]:variation-state-altered:"cysteine"
;[1693..1701]:variation-location:"codon 12"
;[1702..1711]:variation-state-altered:"aspartate"
;[1721..1734]:malignancy:"TT-induced HA"
;[1756..1764]:variation-location:"codon 12"
;[1765..1774]:variation-state-altered:"aspartate"
;[1775..1790]:malignancy:"sporadic tumors"
(SENT
  (S
    (PP (IN:[1603..1605] In)
      (NP (NN:[1606..1614] addition)))
    (,:[1614..1615] ,)
    (NP-SBJ (DT:[1616..1617] a) (JJ:[1618..1624] second)
      (NML
        (NML (NN:[1625..1630] codon) (CD:[1631..1633] 12))
        (HYPH:[1633..1634] -) (NN:[1634..1642] cysteine))
      (JJ:[1644..1650] mutant) (NN:[1651..1655] cell)
       (NN:[1656..1666] population))
    (VP (VBD:[1667..1670] was)
      (ADJP-PRD (JJ:[1671..1678] present))
      (PP-LOC
        (PP (IN:[1679..1681] in)
          (NP
            (NP (CD:[1682..1685] one))
            (PP (IN:[1686..1688] of)
              (NP (CD:[1689..1692] two)
                (ADJP
                  (NML
                    (NML (NN:[1693..1698] codon) (CD:[1699..1701] 12))
                    (HYPH:[1701..1702] -) (NN:[1702..1711] aspartate))
                  (VBN:[1712..1719] mutated))
                
                (ADJP (NN:[1721..1723] TT) (HYPH:[1723..1724] -)
                      (VBN:[1724..1731] induced))
                (NN:[1732..1734] HA)))))
        (CC:[1735..1738] and)
        (PP (IN:[1739..1741] in)
          (NP
            (NP (CD:[1742..1747] three))
            (PP (IN:[1748..1750] of)
              (NP (CD:[1751..1755] five)
                (NML
                  (NML (NN:[1756..1761] codon) (CD:[1762..1764] 12))
                  (HYPH:[1764..1765] -) (NN:[1765..1774] aspartate))
                 (JJ:[1775..1783] sporadic) (NNS:[1784..1790] tumors)))))))
    (.:[1790..1791] .)))

;sentence 15 Span:1792..1938
;Of these  four tumors, three contained both aspartate and cysteine mutations
;and were  composed of multiple nodules; the fourth was a single mass.
;[1807..1813]:malignancy:"tumors"
;[1836..1845]:variation-state-altered:"aspartate"
;[1850..1858]:variation-state-altered:"cysteine"
;[1859..1868]:variation-event:"mutations"
(SENT
  (S
    (PP-1 (IN:[1792..1794] Of)
      (NP (DT:[1795..1800] these) (CD:[1802..1806] four)
          (NNS:[1807..1813] tumors)))
    (,:[1813..1814] ,)
    (S
      (NP-SBJ-3
        (NP (CD:[1815..1820] three))
        (PP-1 (-NONE-:[1820..1820] *T*)))
      (VP
        (VP (VBD:[1821..1830] contained)
          (NP (CC:[1831..1835] both)
            (NP (NN:[1836..1845] aspartate)
              (NML-2 (-NONE-:[1845..1845] *P*)))
            (CC:[1846..1849] and)
            (NP (NN:[1850..1858] cysteine)
              (NML-2 (NNS:[1859..1868] mutations)))))
        (CC:[1869..1872] and)
        (VP (VBD:[1873..1877] were)
          (VP (VBN:[1879..1887] composed)
            (NP-3 (-NONE-:[1887..1887] *))
            (PP-CLR (IN:[1888..1890] of)
              (NP (JJ:[1891..1899] multiple) (NNS:[1900..1907] nodules)))))))
    (::[1907..1908] ;)
    (S
      (NP-SBJ
        (NP (DT:[1909..1912] the) (JJ:[1913..1919] fourth))
        (PP-1 (-NONE-:[1919..1919] *T*)))
      (VP (VBD:[1920..1923] was)
        (NP-PRD (DT:[1924..1925] a) (JJ:[1926..1932] single)
                (NN:[1933..1937] mass))))
    (.:[1937..1938] .)))

;sentence 16 Span:1939..2031
;Seventeen tumors had  multiple nodules; whereas 5 had a K-ras-2 mutation, 12
;were wild-type.
;[1949..1955]:malignancy:"tumors"
;[1995..2002]:gene-rna:"K-ras-2"
;[2003..2011]:variation-event:"mutation"
(SENT
  (S
    (NP-SBJ (CD:[1939..1948] Seventeen) (NNS:[1949..1955] tumors))
    (VP (VBD:[1956..1959] had)
      (NP (JJ:[1961..1969] multiple) (NNS:[1970..1977] nodules))
      (::[1977..1978] ;)
      (SBAR-ADV (IN:[1979..1986] whereas)
        (S
          (S
            (NP-SBJ (CD:[1987..1988] 5))
            (VP (VBD:[1989..1992] had)
              (NP (DT:[1993..1994] a) (NN:[1995..2002] K-ras-2)
                  (NN:[2003..2011] mutation))))
          (,:[2011..2012] ,)
          (S
            (NP-SBJ (CD:[2013..2015] 12))
            (VP (VBD:[2016..2020] were)
              (NP-PRD (JJ:[2021..2025] wild) (HYPH:[2025..2026] -)
                      (NN:[2026..2030] type)))))))
    (.:[2030..2031] .)))

;sentence 17 Span:2032..2338
;The  molecular pathology of both sporadic and TT-induced HA is characterized
;by a  high rate of K-ras-2 mutations characteristic of oxidative damage (ie,
;G:C > A:T  and G:C > T:A mutations) resulting in two mutated population sets:
;codon 12 GGT  > GAT and GGT > TGT (glycine to aspartic acid and cysteine).
;[2065..2073]:malignancy:"sporadic"
;[2078..2088]:malignancy:"TT-induced"
;[2089..2091]:malignancy:"HA"
;[2128..2135]:gene-rna:"K-ras-2"
;[2136..2145]:variation-event:"mutations"
;[2186..2189]:variation-state-original:"G:C"
;[2192..2195]:variation-state-altered:"A:T"
;[2201..2204]:variation-state-original:"G:C"
;[2207..2210]:variation-state-altered:"T:A"
;[2211..2220]:variation-event:"mutations"
;[2264..2272]:variation-location:"codon 12"
;[2273..2276]:variation-state-original:"GGT"
;[2280..2283]:variation-state-altered:"GAT"
;[2288..2291]:variation-state-original:"GGT"
;[2294..2297]:variation-state-altered:"TGT"
;[2299..2306]:variation-state-original:"glycine"
;[2310..2323]:variation-state-altered:"aspartic acid"
;[2328..2336]:variation-state-altered:"cysteine"
(SENT
  (S
    (NP-SBJ-2
      (NP (DT:[2032..2035] The) (JJ:[2037..2046] molecular)
          (NN:[2047..2056] pathology))
      (PP (IN:[2057..2059] of)
        (NP (CC:[2060..2064] both)
          (NP (JJ:[2065..2073] sporadic)
            (NML-1 (-NONE-:[2073..2073] *P*)))
          (CC:[2074..2077] and)
          (NP
            (ADJP (NN:[2078..2080] TT) (HYPH:[2080..2081] -)
                  (VBN:[2081..2088] induced))
            (NML-1 (NN:[2089..2091] HA))))))
    (VP (VBZ:[2092..2094] is)
      (VP (VBN:[2095..2108] characterized)
        (NP-2 (-NONE-:[2108..2108] *))
        (PP (IN:[2109..2111] by)
          (NP-LGS
            (NP
              (NP
                (NP (DT:[2112..2113] a) (JJ:[2115..2119] high)
                    (NN:[2120..2124] rate))
                (PP (IN:[2125..2127] of)
                  (NP (NN:[2128..2135] K-ras-2) (NNS:[2136..2145] mutations))))
              (ADJP (JJ:[2146..2160] characteristic)
                (PP (IN:[2161..2163] of)
                  (NP (JJ:[2164..2173] oxidative) (NN:[2174..2180] damage))))
              (PRN (-LRB-:[2181..2182] -LRB-)
                (NP
                  (ADVP (FW:[2182..2184] ie))
                  (,:[2184..2185] ,)
                  (NP
                    (NP
                      (NML
                        (NML (NN:[2186..2189] G:C))
                        (PP (SYM:[2190..2191] >)
                          (NP (NN:[2192..2195] A:T))))
                      (NML-3 (-NONE-:[2195..2195] *P*)))
                    (CC:[2197..2200] and)
                    (NP
                      (NML
                        (NML (NN:[2201..2204] G:C))
                        (PP (SYM:[2205..2206] >)
                          (NP (NN:[2207..2210] T:A))))
                      (NML-3 (NNS:[2211..2220] mutations)))))
                (-RRB-:[2220..2221] -RRB-)))
            (VP (VBG:[2222..2231] resulting)
              (PP-CLR (IN:[2232..2234] in)
                (NP
                  (NP (CD:[2235..2238] two) (VBN:[2239..2246] mutated)
                      (NN:[2247..2257] population) (NNS:[2258..2262] sets))
                  (::[2262..2263] :)
                  (NP
                    (NP
                      (NML-4 (NN:[2264..2269] codon) (CD:[2270..2272] 12))
                      (NML
                        (NML (NN:[2273..2276] GGT))
                        (PP (SYM:[2278..2279] >)
                          (NP (NN:[2280..2283] GAT)))))
                    (CC:[2284..2287] and)
                    (NP
                      (NML-4 (-NONE-:[2287..2287] *P*))
                      (NML
                        (NML (NN:[2288..2291] GGT))
                        (PP (SYM:[2292..2293] >)
                          (NP (NN:[2294..2297] TGT))))
                      (PRN (-LRB-:[2298..2299] -LRB-)
                        (NP
                          (NP (NN:[2299..2306] glycine))
                          (PP (TO:[2307..2309] to)
                            (NP
                              (NP (JJ:[2310..2318] aspartic)
                                  (NN:[2319..2323] acid))
                              (CC:[2324..2327] and)
                              (NP (NN:[2328..2336] cysteine)))))
                        (-RRB-:[2336..2337] -RRB-)))))))))))
    (.:[2337..2338] .)))

;sentence 18 Span:2339..2531
;This is, to date,  the first study to characterize the K-ras-2 gene mutations
;within human sporadic  and TT-induced HA by direct sequence analysis and
;denaturing gradient gel  electrophoresis.
;[2394..2401]:gene-rna:"K-ras-2"
;[2430..2438]:malignancy:"sporadic"
;[2444..2454]:malignancy:"TT-induced"
;[2455..2457]:malignancy:"HA"
(SENT
  (S
    (NP-SBJ (DT:[2339..2343] This))
    (VP (VBZ:[2344..2346] is) (,:[2346..2347] ,)
      (PP-TMP (TO:[2348..2350] to)
        (NP (NN:[2351..2355] date)))
      (,:[2355..2356] ,)
      (NP-PRD
        (NP (DT:[2358..2361] the) (JJ:[2362..2367] first)
            (NN:[2368..2373] study))
        (S
          (NP-SBJ (-NONE-:[2373..2373] *))
          (VP (TO:[2374..2376] to)
            (VP (VB:[2377..2389] characterize)
              (NP
                (NP (DT:[2390..2393] the) (NN:[2394..2401] K-ras-2)
                    (NN:[2402..2406] gene) (NNS:[2407..2416] mutations))
                (PP (IN:[2417..2423] within)
                  (NP
                    (NP (JJ:[2424..2429] human) (JJ:[2430..2438] sporadic)
                      (NML-1 (-NONE-:[2438..2438] *P*)))
                    (CC:[2440..2443] and)
                    (NP
                      (ADJP (NN:[2444..2446] TT) (HYPH:[2446..2447] -)
                            (VBN:[2447..2454] induced))
                      (NML-1 (NN:[2455..2457] HA))))))
              (PP-MNR (IN:[2458..2460] by)
                (NP
                  (NP (JJ:[2461..2467] direct) (NN:[2468..2476] sequence)
                      (NN:[2477..2485] analysis))
                  (CC:[2486..2489] and)
                  (NP (VBG:[2490..2500] denaturing) (NN:[2501..2509] gradient)
                      (NN:[2510..2513] gel) (NN:[2515..2530] electrophoresis)))))))))
    (.:[2530..2531] .)))

;sentence 19 Span:2532..2796
;These data further support the hypothesis linking  adduct-forming vinyl
;chloride exposure to HA containing a much higher frequency  of K-ras-2
;mutations and a mutational spectrum characteristic of chloroethylene  oxide,
;a carcinogenic metabolite of vinyl chloride.
;[2625..2627]:malignancy:"HA"
;[2667..2674]:gene-rna:"K-ras-2"
(SENT
  (S
    (NP-SBJ (DT:[2532..2537] These) (NNS:[2538..2542] data))
    (ADVP (RBR:[2543..2550] further))
    (VP (VBP:[2551..2558] support)
      (NP
        (NP (DT:[2559..2562] the) (NN:[2563..2573] hypothesis))
        (VP (VBG:[2574..2581] linking)
          (NP
            (NP
              (ADJP (NN:[2583..2589] adduct) (HYPH:[2589..2590] -)
                    (VBG:[2590..2597] forming))
              (NN:[2598..2603] vinyl) (NN:[2604..2612] chloride)
               (NN:[2613..2621] exposure))
            (PP (TO:[2622..2624] to)
              (NP
                (NP
                  (NP (NN:[2625..2627] HA))
                  (VP (VBG:[2628..2638] containing)
                    (NP
                      (NP (DT:[2639..2640] a)
                        (ADJP (RB:[2641..2645] much) (JJR:[2646..2652] higher))
                        (NN:[2653..2662] frequency))
                      (PP (IN:[2664..2666] of)
                        (NP (NN:[2667..2674] K-ras-2)
                            (NNS:[2675..2684] mutations))))))
                (CC:[2685..2688] and)
                (NP
                  (NP (DT:[2689..2690] a) (JJ:[2691..2701] mutational)
                      (NN:[2702..2710] spectrum))
                  (ADJP (JJ:[2711..2725] characteristic)
                    (PP (IN:[2726..2728] of)
                      (NP
                        (NP (NN:[2729..2743] chloroethylene)
                            (NN:[2745..2750] oxide))
                        (,:[2750..2751] ,)
                        (NP
                          (NP (DT:[2752..2753] a) (JJ:[2754..2766] carcinogenic)
                              (NN:[2767..2777] metabolite))
                          (PP (IN:[2778..2780] of)
                            (NP (NN:[2781..2786] vinyl)
                                (NN:[2787..2795] chloride))))))))))))))
    (.:[2795..2796] .)))

;section 20 Span:2800..2844
;PMID: 9010458 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2800..2804] PMID) (::[2804..2805] :) (CD:[2806..2813] 9010458)
        (NN:[2814..2815] -LSB-) (NNP:[2815..2821] PubMed) (::[2822..2823] -)
        (NN:[2824..2831] indexed) (IN:[2832..2835] for)
        (NNP:[2836..2844] MEDLINE-RSB-)))
